Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
28.9M
-
Shares change
-
+2.9M
-
Total reported value, excl. options
-
$87.6M
-
Value change
-
+$7.8M
-
Put/Call ratio
-
1.46
-
Number of buys
-
40
-
Number of sells
-
-48
-
Price
-
$3.03
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2021
119 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2021.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.9M shares
of 193M outstanding shares and own 14.95% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.98M shares), BlackRock Inc. (5.84M shares), VANGUARD GROUP INC (3.74M shares), Hudson Bay Capital Management LP (1.8M shares), OSAIC HOLDINGS, INC. (1.37M shares), GEODE CAPITAL MANAGEMENT, LLC (1.29M shares), STATE STREET CORP (1.16M shares), Point72 Asset Management, L.P. (1M shares), NORTHERN TRUST CORP (719K shares), and PRIMECAP MANAGEMENT CO/CA/ (500K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.